Resmed INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
RMD
Resmed INCResMed Inc. announced robust first-quarter fiscal year 2026 results, with net revenue up 9% and diluted earnings per share increasing by 12%, driven by strong demand in Sleep and Breathing Health products and improved gross margins.
NYSE
RMD
Resmed INCResMed Inc. announces an 8% increase in net revenue for the third quarter of fiscal year 2025, driven by strong performance in both Sleep and Breathing Health and Residential Care Software segments.
NYSE
RMD
Resmed INCResMed Inc. announces a 10% increase in net revenue for the quarter ended December 31, 2024, fueled by strong performance in Sleep and Breathing Health and Residential Care Software segments.
NYSE
RMD
Resmed INC10-Q: ResMed Inc. Reports Strong Q1 2025 Results, Driven by Increased Demand and Operational Efficiencies
ResMed Inc. announced a robust first quarter for fiscal year 2025, with significant revenue growth and improved profitability.
NYSE
RMD
Resmed INC10-Q: ResMed Inc. Reports 7% Revenue Growth in Q3 2024, Driven by Strong Demand and Strategic Initiatives
ResMed Inc. announced a 7% increase in revenue for the third quarter of 2024, alongside improved gross margins and diluted earnings per share.
NYSE
RMD
Resmed INC10-Q: ResMed Inc. Reports 12% Revenue Increase in Latest Quarter, Driven by Strong Device and SaaS Growth
ResMed Inc. saw a 12% increase in revenue for the quarter ended December 31, 2023, driven by growth in both its Sleep and Respiratory Care products and Software as a Service (SaaS) segments.